Korro Bio Inc KRRO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society
-
Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates
-
Korro to Participate in Upcoming Investor Conferences
-
Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors
-
Korro to Participate in Upcoming September Investor and Scientific Conferences
-
Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates
Trading Information
- Previous Close Price
- $34.51
- Day Range
- $32.60–35.18
- 52-Week Range
- $9.15–97.91
- Bid/Ask
- $13.37 / $37.25
- Market Cap
- $310.77 Mil
- Volume/Avg
- 70,010 / 65,103
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 101
- Website
- https://www.korrobio.com
Comparables
Valuation
|
Metric
|
KRRO
|
TNYA
|
JSPR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.57 | 1.14 | 2.83 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
KRRO
TNYA
JSPR
Financial Strength
|
Metric
|
KRRO
|
TNYA
|
JSPR
|
|---|---|---|---|
Quick Ratio | 12.56 | 5.94 | 10.63 |
Current Ratio | 13.18 | 6.28 | 10.79 |
Interest Coverage | — | — | — |
Quick Ratio
KRRO
TNYA
JSPR
Profitability
|
Metric
|
KRRO
|
TNYA
|
JSPR
|
|---|---|---|---|
Return on Assets (Normalized) | −42.42% | −55.72% | −50.56% |
Return on Equity (Normalized) | −86.02% | −66.08% | −58.00% |
Return on Invested Capital (Normalized) | −63.45% | −64.65% | −61.81% |
Return on Assets
KRRO
TNYA
JSPR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Gwzcsgykc | Dqjb | $524.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Nmlzcsvp | Cxfwtw | $120.0 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Jlcnmjc | Nbmss | $115.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Wyvqnyfp | Cfsfcf | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Cccvsdctq | Twdv | $32.4 Bil | |||
| BioNTech SE ADR
BNTX
| Vjfxkdwyr | Dzrf | $28.2 Bil | |||
| Moderna Inc
MRNA
| Bhystkd | Xdsd | $25.7 Bil | |||
| United Therapeutics Corp
UTHR
| Spmfqmqb | Zyjf | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Stptmtd | Tsywbz | $13.4 Bil | |||
| Incyte Corp
INCY
| Kyswtlqh | Zqzswm | $12.7 Bil |
United States